Immune profiles of pre-frail people living with HIV-1: a prospective longitudinal study.
Journal
Immunity & ageing : I & A
ISSN: 1742-4933
Titre abrégé: Immun Ageing
Pays: England
ID NLM: 101235427
Informations de publication
Date de publication:
13 Mar 2024
13 Mar 2024
Historique:
received:
30
11
2023
accepted:
06
02
2024
medline:
14
3
2024
pubmed:
14
3
2024
entrez:
14
3
2024
Statut:
epublish
Résumé
People living with HIV (PLWH) are at risk of frailty, which is predictive for death. As an overactivity of the immune system is thought to fuel frailty, we characterized the immune activation profiles linked to frailty. We quantified twenty-seven activation markers in forty-six virological responders (four females and forty-two males; median age, 74 years; median duration of infection, 24 years; median duration of undetectability, 13 years), whose frailty was determined according to the Fried criteria. T cell and NK cell activation was evaluated by flow cytometry, using a panel of cell surface markers. Soluble markers of inflammation, and monocyte activation and endothelial activation were measured by ELISA. The participants' immune activation was profiled by an unsupervised double hierarchical clustering analysis. We used ANOVA p-values to rank immunomarkers most related to Fried score. A Linear Discriminant Analysis (LDA) was performed to link immune activation markers to frailty. 41% of the participants were pre-frail, including 24% with a Fried score of 1, and 17% with a Fried score of 2. ANOVA identified the 14 markers of T cell, monocyte, NK cell, endothelial activation, and inflammation the most linked to Fried 3 classes. The LDA performed with these 14 markers was capable of discriminating volunteers according to their Fried score. Two out of the 5 immune activation profiles revealed by the hierarchical clustering were linked to and predictive of pre-frailty. These two profiles were characterized by a low percentage of CD4 T cells and a high percentage of CD8 T cells, activated CD4 T cells, CD8 T cells, and NK cells, and inflammation. We identified a particular immune activation profile associated with pre-frailty in PLWH. Profiling participants at risk of developing frailty might help to tailor the screening and prevention of medical complications fueled by loss of robustness. Further studies will indicate whether this frailty signature is specific or not of HIV infection, and whether it also precedes frailty in the general population.
Sections du résumé
BACKGROUND
BACKGROUND
People living with HIV (PLWH) are at risk of frailty, which is predictive for death. As an overactivity of the immune system is thought to fuel frailty, we characterized the immune activation profiles linked to frailty.
METHODS
METHODS
We quantified twenty-seven activation markers in forty-six virological responders (four females and forty-two males; median age, 74 years; median duration of infection, 24 years; median duration of undetectability, 13 years), whose frailty was determined according to the Fried criteria. T cell and NK cell activation was evaluated by flow cytometry, using a panel of cell surface markers. Soluble markers of inflammation, and monocyte activation and endothelial activation were measured by ELISA. The participants' immune activation was profiled by an unsupervised double hierarchical clustering analysis. We used ANOVA p-values to rank immunomarkers most related to Fried score. A Linear Discriminant Analysis (LDA) was performed to link immune activation markers to frailty.
RESULTS
RESULTS
41% of the participants were pre-frail, including 24% with a Fried score of 1, and 17% with a Fried score of 2. ANOVA identified the 14 markers of T cell, monocyte, NK cell, endothelial activation, and inflammation the most linked to Fried 3 classes. The LDA performed with these 14 markers was capable of discriminating volunteers according to their Fried score. Two out of the 5 immune activation profiles revealed by the hierarchical clustering were linked to and predictive of pre-frailty. These two profiles were characterized by a low percentage of CD4 T cells and a high percentage of CD8 T cells, activated CD4 T cells, CD8 T cells, and NK cells, and inflammation.
CONCLUSIONS
CONCLUSIONS
We identified a particular immune activation profile associated with pre-frailty in PLWH. Profiling participants at risk of developing frailty might help to tailor the screening and prevention of medical complications fueled by loss of robustness. Further studies will indicate whether this frailty signature is specific or not of HIV infection, and whether it also precedes frailty in the general population.
Identifiants
pubmed: 38481213
doi: 10.1186/s12979-024-00416-5
pii: 10.1186/s12979-024-00416-5
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20Subventions
Organisme : MSDAVENIR
ID : DS-2016-0010
Informations de copyright
© 2024. The Author(s).
Références
Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol Biol Sci Med Sci. 2001;56(3):M146–56.
doi: 10.1093/gerona/56.3.M146
Kooij KW, Wit FW, Schouten J, van der Valk M, Godfried MH, Stolte IG, et al. HIV infection is independently associated with frailty in middle-aged HIV type 1-infected individuals compared with similar but uninfected controls. AIDS. 2016;30(2):241–50.
pubmed: 26684821
doi: 10.1097/QAD.0000000000000910
Justice AC, Freiberg MS, Tracy R, Kuller L, Tate JP, Goetz MB, et al. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis. 2012;54(7):984–94.
pubmed: 22337823
pmcid: 3297653
doi: 10.1093/cid/cir989
Guaraldi G, Brothers TD, Zona S, Stentarelli C, Carli F, Malagoli A, et al. A frailty index predicts survival and incident multimorbidity independent of markers of HIV disease severity. AIDS. 2015;29(13):1633–41.
pubmed: 26372273
doi: 10.1097/QAD.0000000000000753
Allavena C, Blain H, Abulizi X, Slama L, Katlama C, Delobel P, et al. Prevalence and risk factors of frailty among adults living with HIV aged 70 years or older. AIDS. 2023;37(1):183–9.
pubmed: 36250271
doi: 10.1097/QAD.0000000000003403
Althoff KN, Jacobson LP, Cranston RD, Detels R, Phair JP, Li X, et al. Age, comorbidities, and AIDS predict a frailty phenotype in men who have sex with men. J Gerontol Biol Sci Med Sci. 2014;69(2):189–98.
doi: 10.1093/gerona/glt148
Erlandson KM, Allshouse AA, Jankowski CM, Lee EJ, Rufner KM, Palmer BE, et al. Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy. J Infect Dis. 2013;208(2):249–59.
pubmed: 23559466
pmcid: 3685225
doi: 10.1093/infdis/jit147
Onen NF, Agbebi A, Shacham E, Stamm KE, Onen AR, Overton ET. Frailty among HIV-infected persons in an urban outpatient care setting. J Infect. 2009;59(5):346–52.
pubmed: 19706308
doi: 10.1016/j.jinf.2009.08.008
Piggott DA, Muzaale AD, Mehta SH, Brown TT, Patel KV, Leng SX, et al. Frailty, HIV infection, and mortality in an aging cohort of injection drug users. PLoS ONE. 2013;8(1):e54910.
pubmed: 23382997
pmcid: 3561408
doi: 10.1371/journal.pone.0054910
Erlandson KM, Allshouse AA, Jankowski CM, Duong S, Mawhinney S, Kohrt WM, et al. Comparison of functional status instruments in HIV-infected adults on effective antiretroviral therapy. HIV Clin Trials. 2012;13(6):324–34.
pubmed: 23195670
pmcid: 4379206
doi: 10.1310/hct1306-324
Terzian AS, Holman S, Nathwani N, Robison E, Weber K, Young M, et al. Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of cART. J Womens Health (Larchmt). 2009;18(12):1965–74.
pubmed: 20044858
doi: 10.1089/jwh.2008.1090
Yeoh HL, Cheng AC, Cherry CL, Weir JM, Meikle PJ, Hoy JF, et al. Immunometabolic and lipidomic markers Associated with the Frailty Index and Quality of Life in Aging HIV + Men on antiretroviral therapy. EBioMedicine. 2017;22:112–21.
pubmed: 28754302
pmcid: 5552224
doi: 10.1016/j.ebiom.2017.07.015
Erlandson KM, Allshouse AA, Jankowski CM, MaWhinney S, Kohrt WM, Campbell TB. Functional impairment is associated with low bone and muscle mass among persons aging with HIV infection. J Acquir Immune Defic Syndr. 2013;63(2):209–15.
pubmed: 23392468
pmcid: 3654048
doi: 10.1097/QAI.0b013e318289bb7e
Masters MC, Perez J, Wu K, Ellis RJ, Goodkin K, Koletar SL, et al. Baseline neurocognitive impairment (NCI) is Associated With Incident Frailty but Baseline Frailty does not Predict Incident NCI in older persons with Human Immunodeficiency Virus (HIV). Clin Infect Dis. 2021;73(4):680–8.
pubmed: 34398957
pmcid: 8499706
doi: 10.1093/cid/ciab122
Ianas V, Berg E, Mohler MJ, Wendel C, Klotz SA. Antiretroviral therapy protects against frailty in HIV-1 infection. J Int Assoc Provid AIDS Care. 2013;12(1):62–6.
pubmed: 23042791
doi: 10.1177/1545109712457241
Pathai S, Gilbert C, Weiss HA, Cook C, Wood R, Bekker LG, et al. Frailty in HIV-infected adults in South Africa. J Acquir Immune Defic Syndr. 2013;62(1):43–51.
pubmed: 23018372
pmcid: 3772340
doi: 10.1097/QAI.0b013e318273b631
Fulop T, Witkowski JM, Olivieri F, Larbi A. The integration of inflammaging in age-related diseases. Semin Immunol. 2018;40:17–35.
pubmed: 30287177
doi: 10.1016/j.smim.2018.09.003
Nazmi A, Victora CG. Socioeconomic and racial/ethnic differentials of C-reactive protein levels: a systematic review of population-based studies. BMC Public Health. 2007;7:212.
pubmed: 17705867
pmcid: 2018719
doi: 10.1186/1471-2458-7-212
Halaris A. Co-morbidity between cardiovascular pathology and depression: role of inflammation. Mod Trends Pharmacopsychiatry. 2013;28:144–61.
pubmed: 25224897
doi: 10.1159/000343981
Younas M, Psomas C, Reynes J, Corbeau P. Immune activation in the course of HIV-1 infection: causes, phenotypes and persistence under therapy. HIV Med. 2016;17:89–105.
pubmed: 26452565
doi: 10.1111/hiv.12310
Margolick JB, Bream JH, Martinez-Maza O, Lopez J, Li X, Phair JP, et al. Frailty and circulating markers of inflammation in HIV + and HIV- Men in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2017;74(4):407–17.
pubmed: 28225718
pmcid: 5365031
doi: 10.1097/QAI.0000000000001261
Piggott DA, Varadhan R, Mehta SH, Brown TT, Li H, Walston JD, et al. Frailty, inflammation, and Mortality among persons Aging with HIV infection and Injection Drug Use. J Gerontol Biol Sci Med Sci. 2015;70(12):1542–7.
doi: 10.1093/gerona/glv107
Leng S, Chaves P, Koenig K, Walston J. Serum interleukin-6 and hemoglobin as physiological correlates in the geriatric syndrome of frailty: a pilot study. J Am Geriatr Soc. 2002;50(7):1268–71.
pubmed: 12133023
doi: 10.1046/j.1532-5415.2002.50315.x
Margolick JB, Bream JH, Nilles TL, Li H, Langan SJ, Deng S, et al. Relationship between T-Cell responses to CMV, markers of inflammation, and Frailty in HIV-uninfected and HIV-infected men in the Multicenter AIDS Cohort Study. J Infect Dis. 2018;218(2):249–58.
pubmed: 29529309
pmcid: 6009694
doi: 10.1093/infdis/jiy005
Derry HM, Johnston CD, Burchett CO, Brennan-Ing M, Karpiak S, Zhu YS, et al. Links between inflammation, Mood, and physical function among older adults with HIV. J Gerontol B Psychol Sci Soc Sci. 2022;77(1):50–60.
pubmed: 33580236
doi: 10.1093/geronb/gbab027
Hamilton GF, McDonald C, Chenier TC. Measurement of grip strength: validity and reliability of the sphygmomanometer and jamar grip dynamometer. J Orthop Sports Phys Ther. 1992;16(5):215–9.
pubmed: 18796752
doi: 10.2519/jospt.1992.16.5.215
Lee PH, Macfarlane DJ, Lam TH, Stewart SM. Validity of the International Physical Activity Questionnaire Short Form (IPAQ-SF): a systematic review. Int J Behav Nutr Phys Act. 2011;8:115.
pubmed: 22018588
pmcid: 3214824
doi: 10.1186/1479-5868-8-115
Raho-Moussa M, Guiguet M, Michaud C, Honore P, Palacios C, Boue F, et al. Respective roles of migration and social deprivation for virological non-suppression in HIV-infected adults on antiretroviral therapy in France. PLoS ONE. 2019;14(3):e0213019.
pubmed: 30845270
pmcid: 6405133
doi: 10.1371/journal.pone.0213019
Cezar R, Winter A, Desigaud D, Pastore M, Kundura L, Dupuy A-M, et al. Identification of distinct immune activation profiles in adult humans. Sci Rep. 2020;10(1):20824.
pubmed: 33257766
pmcid: 7704615
doi: 10.1038/s41598-020-77707-6
Cezar R, Desigaud D, Pastore M, Kundura L, Dupuy AM, Cognot C, et al. Insulin resistance is linked to a specific profile of immune activation in human subjects. Sci Rep. 2021;11(1):12314.
pubmed: 34112902
pmcid: 8192510
doi: 10.1038/s41598-021-91758-3
Soysal P, Stubbs B, Lucato P, Luchini C, Solmi M, Peluso R, et al. Inflammation and frailty in the elderly: a systematic review and meta-analysis. Ageing Res Rev. 2016;31:1–8.
pubmed: 27592340
doi: 10.1016/j.arr.2016.08.006
Puzianowska-Kuznicka M, Owczarz M, Wieczorowska-Tobis K, Nadrowski P, Chudek J, Slusarczyk P, et al. Interleukin-6 and C-reactive protein, successful aging, and mortality: the PolSenior study. Immun Ageing. 2016;13:21.
pubmed: 27274758
pmcid: 4891873
doi: 10.1186/s12979-016-0076-x
Walker KA, Hoogeveen RC, Folsom AR, Ballantyne CM, Knopman DS, Windham BG, et al. Midlife systemic inflammatory markers are associated with late-life brain volume: the ARIC study. Neurology. 2017;89(22):2262–70.
pubmed: 29093073
pmcid: 5705246
doi: 10.1212/WNL.0000000000004688
De Fanis U, Wang GC, Fedarko NS, Walston JD, Casolaro V, Leng SX. T-lymphocytes expressing CC chemokine receptor-5 are increased in frail older adults. J Am Geriatr Soc. 2008;56(5):904–8.
pubmed: 18384587
pmcid: 2662852
doi: 10.1111/j.1532-5415.2008.01673.x
Wang GC, Casolaro V. Immunologic changes in frail older adults. Transl Med UniSa. 2014;9:1–6.
pubmed: 24809027
pmcid: 4012368
Johnstone J, Parsons R, Botelho F, Millar J, McNeil S, Fulop T, et al. T-Cell phenotypes predictive of Frailty and Mortality in Elderly nursing home residents. J Am Geriatr Soc. 2017;65(1):153–9.
pubmed: 27775813
doi: 10.1111/jgs.14507
Rodriguez IJ, Lalinde Ruiz N, Llano Leon M, Martinez Enriquez L, Montilla Velasquez MDP, Ortiz Aguirre JP, et al. Immunosenescence Study of T Cells: a systematic review. Front Immunol. 2020;11:604591.
pubmed: 33519813
doi: 10.3389/fimmu.2020.604591
Leng SX, Tian X, Matteini A, Li H, Hughes J, Jain A, et al. IL-6-independent association of elevated serum neopterin levels with prevalent frailty in community-dwelling older adults. Age Ageing. 2011;40(4):475–81.
pubmed: 21586579
pmcid: 3114624
doi: 10.1093/ageing/afr047
Chhetri JK, de Souto Barreto P, Fougere B, Rolland Y, Vellas B, Cesari M. Chronic inflammation and sarcopenia: a regenerative cell therapy perspective. Exp Gerontol. 2018;103:115–23.
pubmed: 29331536
doi: 10.1016/j.exger.2017.12.023
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older people. Age Ageing. 2010;39(4):412–23.
pubmed: 20392703
pmcid: 2886201
doi: 10.1093/ageing/afq034
Lazarus DD, Moldawer LL, Lowry SF. Insulin-like growth factor-1 activity is inhibited by interleukin-1 alpha, tumor necrosis factor-alpha, and interleukin-6. Lymphokine Cytokine Res. 1993;12(4):219–23.
pubmed: 8218594
Borsini A, Cattaneo A, Malpighi C, Thuret S, Harrison NA, Consortium MRCI, et al. Interferon-Alpha reduces human hippocampal neurogenesis and increases apoptosis via activation of distinct STAT1-Dependent mechanisms. Int J Neuropsychopharmacol. 2018;21(2):187–200.
pubmed: 29040650
doi: 10.1093/ijnp/pyx083
de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett. 2008;582(1):97–105.
pubmed: 18053812
doi: 10.1016/j.febslet.2007.11.057
Schmeer C, Kretz A, Wengerodt D, Stojiljkovic M, Witte OW. Dissecting aging and senescence-current concepts and Open lessons. Cells. 2019;8(11).
Psomas C, Younas M, Reynes C, Cezar R, Portalès P, Tuaillon E, et al. One of the immune activation profiles observed in HIV-1-infected adults with suppressed viremia is linked to metabolic syndrome: the ACTIVIH study. EBioMedicine. 2016;8:265–76.
pubmed: 27428436
pmcid: 4919610
doi: 10.1016/j.ebiom.2016.05.008
Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair FS. Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493 737 UK Biobank participants. Lancet Public Health. 2018;3(7):e323–e32.
pubmed: 29908859
pmcid: 6028743
doi: 10.1016/S2468-2667(18)30091-4